Table 2

Renal parameters, treatment and chronic damage in the Euro-Lupus Nephritis Trial Cohort at 10 years of follow-up

AllIVCY
High doseLow dose
Current serum creatinine (mg/dl)1.0 (0.5)1.0 (0.4)1.0 (0.6)
Current 24 h proteinuria (g)0.6 (1.2)0.6 (1.3)0.5 (1.0)
Ongoing GC therapy (% of patients)737175
Ongoing IS therapy (% of patients)565953
Ongoing BP lowering therapy (% of patients)686867
Additional IS drugs ever received† (n)0.7 (0.9)0.7 (0.9)0.7 (0.9)
Ever received MMF (% of patients)303029
Cumulative IVCY dose (g)7.6 (2.5)9.5 (2.5)5.5 (4.8)*
Current SLICC/ACR DI (score)1.1 (1.1)1.0 (1.2)1.1 (1.1)
Cumulative cardiac/arterial events (n patients)743
Cumulative cancers (n patients)716
  • Figures are mean (SD) except where stated otherwise.

  • *p<0.001.

  • †In addition to the per protocol IS drugs.

  • BP, blood pressure; GC, glucocorticoid; IS, immunosuppressive; IVCY, intravenous cyclophosphamide; MMF, mycophenolate mofetil; SLICC/ACR DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.